This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Neurocrine Biosciences' CEO Reviews Phase II Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia (Transcript)

Stocks in this article: NBIX

Neurocrine Biosciences Inc. (NBIX)

Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia Call

March 27, 2012 08:00 am ET

Executives

Kevin Gorman - President & CEO

Jane Sorenson - IR

Chris O'Brien - CMO

Analysts

Thomas Wei - Jefferies

Robyn Karnauskas - Deutsche Bank

Phil Nadeau - Cowen & Company

Jon LeCroy - MKM

Joshua Schimmer - Leerink Swann

Presentation

Operator

Good day everyone and welcome to this Neurocrine announces Phase II Results of the VMAT2 Inhibitor call. At this time all sites are on a listen-only mode (Operator Instructions). As a reminder today's call may be recorded and it's now my pleasure to introduce our first speaker, President and CEO, Mr. Kevin Gorman. Please go ahead sir.

Kevin Gorman

Thank you very much and thank everyone for joining us this morning. I'm joined here with Chris O'Brien, our Chief Medical Officer and Tim Coughlin, our CFO. Before we get started, I would like Jane Sorenson to read our Safe Harbor statement please.

Jane Sorenson

Good morning. I want to remind you of Neurocrine’s Safe Harbor precautions. Certain statements made in the course of this conference call that state the company's or management's intentions, hopes, believes, expectations or predictions of the future are forward-looking statements which are subject to risks and uncertainties. Information concerning factors that could cause the actual results to differ materially from those contained in or implied by the forward-looking statements is contained in the company's SEC filings, including but not limited to the company's annual report on Form 10-K and quarterly reports on Form 10-Q.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,130.88 +156.57 0.92%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,551.0060 +1.78 0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs